Breaking News Instant updates and real-time market news.

OCX

OncoCyte

$2.65

0.16 (6.43%)

, CLSD

Clearside Biomedical

$2.21

-0.11 (-4.74%)

17:39
01/10/20
01/10
17:39
01/10/20
17:39

Fly Intel: After Hours Movers

HIGHER: OncoCyte (OCX), up 4.5% after agreeing to acquire Insight Genetics for about $12M. LOWER: Clearside Biomedical (CLSD), down 5.5% after filing to sell 3.18M shares of common stock for holders... Boot Barn (BOOT), down 5.4% after reporting preliminary Q3 results.

OCX

OncoCyte

$2.65

0.16 (6.43%)

CLSD

Clearside Biomedical

$2.21

-0.11 (-4.74%)

BOOT

Boot Barn

$45.82

-1.225 (-2.60%)

  • 12

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

OCX OncoCyte
$2.65

0.16 (6.43%)

06/27/19
BNCH
06/27/19
NO CHANGE
Target $7
BNCH
Buy
OncoCyte reaction to DetermaVu delay overdone, says Benchmark
Benchmark analyst Bruce Jackson said that he views yesterday's price action in shares of OncoCyte after the company announced that it needs additional time to complete the CLIA validation study as overdone. The validation process could be converted to an automated one, said the company, which Jackson would view as a positive since it tends to improve overall test performance by removing a source of variability. Jackson, who said he doesn't view the announcement of the delay for the DetermaVu test as a major setback for OncoCyte, sees the associated pullback as a buying opportunity and keeps a Buy rating and $7 price target on the shares.
07/03/19
BNCH
07/03/19
NO CHANGE
BNCH
Speculative Buy
BioTime sale of OncoCyte shares expands shareholder base, says Benchmark
Benchmark analyst Bruce Jackson noted that OncoCyte's (OCX) majority shareholder, BioTime (BTX), is selling 2.25M of its 14.7M shares in the former. He views the share sale as positive for both, noting that BioTime will gain additional capital and OncoCyte will gain a broader shareholder base. BioTime will still hold about 24% of OncoCyte's stock following the deal's completion and Broadwood Partners will be building on its 15.6% stake by acquiring about 1M of the 2.25M shares being offered, noted Jackson, who keeps a Speculative Buy rating on OncoCyte shares.
08/15/19
PIPR
08/15/19
NO CHANGE
PIPR
OncoCyte delayed DetermaVu study by 6-9 months, says Piper Jaffray
OncoCyte management said last night that the CLIA Validation study for DetermaVu will be delayed 6-9 months from now following inconsistencies with the RNA extraction reagents used in the workflow, which was impacting reproducibility of the data, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst pushed out his assumptions for reimbursement and commercialization by six months and lowered his price target for the shares to $5.40 from $6. His new model assumes commercialization in Q3 of 2020 and reimbursement beginning in Q3 of 2021. Quirk keeps an Overweight rating on he shares.
09/05/19
PIPR
09/05/19
NO CHANGE
PIPR
OncoCyte acquisition of Razor Genomics stake 'smart,' says Piper Jaffray
Piper Jaffray analyst William Quirk maintained an Overweight rating and $5.40 price target on OncoCyte after the company announced it was acquiring a 25% stake in Razor Genomics for $10M, with an option to buy the entire company for a value of around $33M, which Quirk called a "smart deal... consistent with OncoCyte's long-term view of menu expansion." Additionally, the analyst was positive as OncoCyte reiterated it was close to restarting the CLIA Clinical Validation process for DetermaVu.
CLSD Clearside Biomedical
$2.21

-0.11 (-4.74%)

10/14/19
ROTH
10/14/19
NO CHANGE
ROTH
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Commenting on the Ophthalmology space, Roth Capital analyst Zegbeh Jallah highlights her conviction for stronger valuations, driven by the increasing number of companies with innovative pipelines, and pending changes at both the FDA and CMS. The analyst suspects that these changes could lead to more wins in the space, which could drive valuations. Further, she cautions investors to keep "their eyes peeled on developments in the space." Jallah sees this as possible relevant for KalVista (KALV), Regenxbio (RGNX), Kala Pharmaceuticals (KALA), Kodiak Sciences (KOD), Regeneron (REGN), Aerie Pharmaceuticals (AERI), Applied Genetic (AGTC), Aldeyra (ALDX), Adverum Biotechnologies (ADVM), Clearside Biomedical (CLSD), Ocugen (OCGN), and many others.
08/22/19
JMPS
08/22/19
NO CHANGE
JMPS
Clearside Biomedical price target lowered to $3 from $4 at JMP Securities
JMP Securities analyst Donald Ellis reiterated an Outperform rating on Clearside Biomedical, but it lowering his price target on shares to $3 from $4 after the FDA requested additional stability data for Xipere, which will delay a final FDA approval and require an NDA re-submission in Q1 of 2020. Ellis added that he now sees Xipere approval in Q3 of 2020.
08/13/19
LDLW
08/13/19
DOWNGRADE
Target $2
LDLW
Hold
Laidlaw downgrades Clearside Biomedical to Hold after Xipere partnering
As previously reported, Laidlaw analyst Francois Brisebois downgraded Clearside Biomedical to Hold from Buy as he believes the company's decision to out-license their main product, Xipere, adds uncertainty for the foreseeable future in terms of topline growth. He lowered his price target on Clearside shares to $2 from $5, stating that he values CLS-TA for U.S. uveitis at $1.50 per share and the company's cash and technology at 50c per share.
12/17/19
JMPS
12/17/19
NO CHANGE
Target $4
JMPS
Outperform
FDA to accept RVO clinial use data from Clearside, says JMP Securities
JMP Securities analyst Donald Ellis reiterated an Outperform rating and $4 price target on Clearside Biomedical after the FDA agreed to accept clinical use data from the macular edema associated with the RVO study, removing the need for an additional clinical use study for the uveitis NDA. The analyst tells investors in a research note that Clearside plans to resubmit the NDA for XIPERE in non-infectious uveitis in 2Q20 and expects an FDA review within six months of submission. He expects Clearside's cash to last until at least the third quarter, but adds that removing the need for the clinical use study likely extends the cash runway.
BOOT Boot Barn
$45.82

-1.225 (-2.60%)

10/15/19
COWN
10/15/19
NO CHANGE
Target $42
COWN
Outperform
Boot Barn share price not fully reflecting competitive positioning, says Cowen
Cowen analyst Oliver Chen Said he would be a buyer of Boot Barn shares heading into earnings as its share price does not fully reflect its competitive positioning and sustainability. The analyst sees upside to the Street's estimates, he expects comps guidance to be raised, and expects impacts from tariffs to be negligible. Chen reiterated his Outperform rating and $42 price target on Boot Barn shares.
11/08/19
JEFF
11/08/19
NO CHANGE
JEFF
Tariff roll backs could be catalyst for footwear, apparel stocks, says Jefferies
Jefferies analyst Janine Stichter noted press reports indicating that the U.S. is considering removing the 15% List 4A tariffs and may not move ahead with the December List 4B tariffs, which she thinks could be a catalyst for the footwear and apparel group from both an EPS and multiple standpoint and a tailwind for overall discretionary spending. She particularly highlighted what she sees as a potentially significant benefit for retailers American Eagle (AEO), Urban Outfitters (URBN) and Boot Barn (BOOT), on which she has Buy ratings. Stichter also lists Chico's (CHS), Abercrombie & Fitch (ANF), Gap (GPS), Steven Madden (SHOO) and Genesco (GCO) among retailers and footwear companies who source heavily from China and have high exposure to direct imports, instead of third party brands.
11/11/19
COWN
11/11/19
NO CHANGE
Target $47
COWN
Outperform
Boot Barn well positioned to get bigger, says Cowen
Cowen analyst Oliver Chen said Boot Barn is a best executor in the Western wear category and he believes they are well positioned to get bigger. He likes its specialty industry leadership, own and branded merchandise, execution and low level fashion risk plus he thinks its segmented marketing and digital focus will propel its ongoing strong comps and unit growth. Chen reiterated his Outperform rating and raised his price target to $47 from $44 on Boot Barn shares.
11/22/19
DADA
11/22/19
NO CHANGE
Target $46
DADA
Buy
Boot Barn price target raised to $46 from $43 at DA Davidson
DA Davidson analyst John Morris raised his price target on Boot Barn to $46 and kept his Buy rating after hosting a non-deal roadshow meeting with its CEO Jim Conroy. The analyst says the discussions have made him more optimistic about the opportunity for the company's back-half of 2019, with business trends "ramping up" into the holiday season. Going into Q3, Morris believes Boot Barn will see "increased store traffic and higher AUR" from the impact of the management's key initiatives.

TODAY'S FREE FLY STORIES

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/17/20
01/17
16:17
01/17/20
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/17/20
01/17
16:16
01/17/20
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
01/17/20
01/17
16:15
01/17/20
16:15
General news
Treasury Market Summary »

Treasury Market Summary:…

LGC

Legacy Acquisition Corp

$10.33

(0.00%)

16:08
01/17/20
01/17
16:08
01/17/20
16:08
Hot Stocks
Legacy Acquisition Corp extends date to consummate proposed business combination »

Legacy Acquisition Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$0.33

-0.015 (-4.41%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Syndicate
Breaking Syndicate news story on Genius Brands »

Genius Brands files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$90.21

1.28 (1.44%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Periodicals
Best Buy board opens investigation into CEO's personal conduct, WSJ says »

The board of Best Buy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.